Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	351	325	181	365	241	190
Market Cap Growth	38.71%	79.47%	-50.50%	51.64%	26.61%	-46.35%
Enterprise Value	532	481	257	351	194	173
PE Ratio	-	-5.21	-1.91	-2.98	-2.64	-1.51
PS Ratio	2.05	1.98	1.64	7.37	11.79	69.92
PB Ratio	-33.82	-47.86	4.00	3.84	7.14	13.18
P/FCF Ratio	-7.16	-6.59	-1.75	-3.78	-2.98	-1.80
P/OCF Ratio	-7.54	-6.90	-1.76	-3.82	-2.99	-1.82
EV/Sales Ratio	3.10	2.94	2.33	7.08	9.50	63.58
EV/EBITDA Ratio	-19.89	-20.28	-3.71	-3.09	-2.45	-1.47
EV/EBIT Ratio	-12.97	-13.05	-3.13	-3.04	-2.41	-1.46
EV/FCF Ratio	-11.34	-9.77	-2.48	-3.63	-2.40	-1.64
Debt / Equity Ratio	-29.28	-33.79	4.38	0.92	2.58	4.04
Debt / EBITDA Ratio	-10.87	-9.66	-2.86	-0.77	-1.10	-0.49
Debt / FCF Ratio	-6.19	-4.65	-1.92	-0.91	-1.08	-0.55
Quick Ratio	1.71	1.17	2.08	1.52	4.99	2.94
Current Ratio	2.37	1.64	2.54	1.80	5.40	3.20
Asset Turnover	0.52	0.50	0.34	0.26	0.13	0.02
Interest Coverage	-1.38	-1.39	-5.81	-16.09	-7.56	-16.60
Return on Equity (ROE)	-16662.60%	-610.80%	-139.90%	-312.60%	-366.20%	-209.30%
Return on Assets (ROA)	-19.60%	-19.10%	-29.00%	-65.00%	-59.60%	-94.40%
Return on Capital (ROIC)	-17.33%	-19.79%	-33.69%	-62.82%	-69.17%	-168.24%
Earnings Yield	-18.37%	-19.18%	-52.34%	-33.59%	-37.82%	-65.99%
FCF Yield	-12.37%	-15.18%	-57.18%	-26.44%	-33.59%	-55.41%
Buyback Yield / Dilution	-2.46%	-1.51%	-71.62%	-85.32%	-63.32%	-116.75%
Total Shareholder Return	-2.46%	-1.51%	-71.62%	-85.32%	-63.32%	-116.75%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).